Sanofi

Moore Kuehn Encourages RADI, PRVB, CVT, and UNVR Investors to Contact Law Firm

Retrieved on: 
Tuesday, March 21, 2023
Blackstone, Sanofi, PLLC, Wall Street, Fraud, Univar Solutions, QT, Security (finance), Bank

Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.

Key Points: 
  • Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
  • Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq.
  • Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
  • Moore Kuehn is a 5-star Google client-rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims.

Enable Biosciences Announces Relaunch of Website for Early Detection of Type 1 Diabetes

Retrieved on: 
Tuesday, March 21, 2023
Carolyn Bertozzi, JDRF, Teplizumab, T1D, Research, MD, SAN, Immune system, Autoimmune disease, Sanofi, Health, Autoantibody, Disease, Pharmaceutical industry, Vaccine

SOUTH SAN FRANCISCO, Calif., March 21, 2023 /PRNewswire/ -- Enable Biosciences, a biotechnology company dedicated to developing innovative diagnostics, announced the relaunch of its website, type1testing.enablebiosciences.com , which offers an at-home testing kit for the early detection of type 1 diabetes.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 21, 2023 /PRNewswire/ -- Enable Biosciences, a biotechnology company dedicated to developing innovative diagnostics, announced the relaunch of its website, type1testing.enablebiosciences.com , which offers an at-home testing kit for the early detection of type 1 diabetes.
  • Type 1 diabetes is an autoimmune disease affecting over 1.6 million people in the United States.
  • The relaunch of the site coincides with the approval of a new therapy for type 1 diabetes.
  • The Enable Biosciences website is now live and accepting orders for the early detection testing kit.

Notice of Compliance issued regarding Rezurock(TM) (belumosudil tablets)

Retrieved on: 
Tuesday, March 21, 2023
Faculty, GVHD, Mouth, MDCM, Eye, Quality of life, Esophagus, Inflammation, Lung, Harvard Medical School, Dana–Farber Cancer Institute, Fibrosis, Assistant professor, Medical director, MD, Patient, Division, Outline of health sciences, Disease, McGill University, Liver, FRCPC, Health, MPH, Health Canada, McGill University Faculty of Medicine and Health Sciences, Skin, Pharmaceutical industry, Dentistry, Hematology, Sanofi, Medicine

This includes fibrosis, which can have a devastating impact on a patient's health and well-being.

Key Points: 
  • This includes fibrosis, which can have a devastating impact on a patient's health and well-being.
  • I welcome the approval of Rezurock™ in Canada because it brings a new treatment option to patients who are experiencing severe and life-threatening symptoms."
  • It was developed specifically for the treatment of chronic graft-versus-host disease and it has anti-fibrotic properties.
  • The availability of Rezurock™ represents an advancement for patients who have undergone a stem cell transplant and require treatment for chronic graft-versus-host disease."

Cytovation appoints Iman Barilero as Chief Development Officer

Retrieved on: 
Tuesday, March 21, 2023
Antigen, Doctor of Pharmacy, Drug development, University, Tufts Center for the Study of Drug Development, Roche, Big Pharma, Cancer, Bristol Myers Squibb, Doctor of Philosophy, CNS, Institut Gustave Roussy, MD, Central nervous system disease, Immune system, Sanofi, Merck, Merck & Co., Pembrolizumab, Pharmacology, Merck Sharp & Dohme Federal Credit Union, Pharmaceutical industry

Bergen, Norway, 21 March 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces that Dr. Iman Barilero has joined the company as Chief Development Officer.

Key Points: 
  • Bergen, Norway, 21 March 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces that Dr. Iman Barilero has joined the company as Chief Development Officer.
  • Dr. Barilero brings three decades of experience as a strategic executive in the global healthcare industry, successfully designing innovative and integrated patient-centric and value-based regulatory development pathways, in all phases of drug development and across all major global pharmaceutical markets.
  • Lars Prestegarden, MD, PhD, CEO of Cytovation, commented: “We’re delighted to have someone with Iman’s wealth of experience join Cytovation as we progress CyPep-1 through clinical development.
  • Iman has worked across Big Pharma and biotech, and her support will be invaluable as the company enters its important next stages of development and growth.”
    Iman Barilero, PharmD, PhD, Cytovation’s Chief Development Officer, added: “CyPep-1 represents an exciting new approach to cancer immunotherapy, and it’s great to be joining Cytovation at a time when the asset has such strong clinical momentum backed by promising early data.

Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis

Retrieved on: 
Tuesday, March 21, 2023
Inflammation, Skin infection, Siliceous ooze, Civil service commission, Regeneron Pharmaceuticals, Parent, Overalls, Quality of life, Atopic dermatitis, Arthralgia, GPER, TCS, Pain, Heart, European Commission, Patient, Risk, Child, Biological soil crust, European, International development, Growth, Infant, Immunology, Ageing, MPH, Conjunctivitis, EC, Red, Human, Eosinophilia, Skin, Caregiver, Safety, Conditional sentence, Disease, Pharmaceutical industry, Vaccine, Medical imaging, Copper, EU, Dupilumab, Sanofi

TARRYTOWN, N.Y. and PARIS, March 21, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent® (dupilumab) in the European Union (EU) to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy. With this approval, Dupixent is the first and only targeted medicine indicated to treat these young children in Europe and the U.S.

Key Points: 
  • “I’ve personally witnessed how this chronic skin disease can disrupt the lives of entire families when left uncontrolled.
  • Between 85% and 90% of patients first develop symptoms before 5 years of age, which can often continue through adulthood.
  • Severe atopic dermatitis may also significantly impact the quality of life of young children and their caregivers.
  • “Too often the parents and caregivers of children with severe atopic dermatitis are left desperate for new treatments to manage this chronic disease.

Techdow USA Announces FDA Approval of Generic Lovenox®, (Enoxaparin Sodium – Preservative Free) In Prefilled Syringes

Retrieved on: 
Monday, March 20, 2023
FDA, Pharmaceutical, Health, Medical Supplies, Akwa Ibom State Association of Nigeria, USA Inc., Sale, Sanofi, Environment, Syringe, Pharmaceutical industry, Fine chemical, Enoxaparin sodium

Techdow USA Inc. (“Techdow USA”), a growing market leader and vertically integrated generic injectables company, today announced the FDA approval of Enoxaparin Sodium (Preservative Free) in Prefilled Syringes for the U.S. market.

Key Points: 
  • Techdow USA Inc. (“Techdow USA”), a growing market leader and vertically integrated generic injectables company, today announced the FDA approval of Enoxaparin Sodium (Preservative Free) in Prefilled Syringes for the U.S. market.
  • “Techdow USA is excited to bring this critical product to institutions, retail and other networks in need of a safe, affordable and reliable source of Enoxaparin,” said Darren Alkins, Chief Executive Officer of Techdow USA.
  • Enoxaparin Sodium (Preservative Free) Prefilled Syringes had US brand and generic sales of approximately $550 million, according to IQVIA Health for the 12 months ending December, 2022.
  • To report SUSPECTED ADVERSE REACTIONS, contact Hepalink USA, Inc./Techdow USA, Inc. at 1-888-355-1375 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

PHARMACEUTICS INTERNATIONAL ONBOARDS NEW LEADERSHIP TEAM TO DRIVE QUALITY, OPERATIONAL IMPROVEMENTS, AND GROWTH

Retrieved on: 
Monday, March 20, 2023
Online, Vaccine, GMP, Human resources, AstraZeneca, Employment, General counsel, Asepsis, Culture, Head, Business operations, EVP, Abbott Laboratories, ISO, Valley, Business, Risk management, Olympus, PII, Thermo Fisher Scientific, Catalent, History, Assistant, Colorado Technical University, CDMO, Acquisition, Project management, Patient, Supply chain, HUNT, Getinge, ICU Medical, CFO, Supply, Grand River Aseptic Manufacturing, Indoxacarb, Management, Fine chemical, Pharmaceutical industry, MD, Sanofi

For over twenty-five years, the company has been providing technical and regulatory capabilities and Pharmaceutics Know-How™.

Key Points: 
  • For over twenty-five years, the company has been providing technical and regulatory capabilities and Pharmaceutics Know-How™.
  • Under Fowlers’ leadership, Pii will focus on the highest level of customer service.
  • Supporting Devan in his expanded role is Sara Frederick, who has joined Pii as Senior Director of Business Operations.
  • He has worked in many HR leadership roles in the medical technology space including Olympus and Thermo Fisher Scientific.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGEN, ADAP, PRVB, XM

Retrieved on: 
Sunday, March 19, 2023
Pfizer, Sale, Silver, In re Caremark International Inc. Derivative Litigation, Advertising, Qualtrics, Fraud, Therapy, Security (finance), Seagen, Sanofi

If you are a Seagen shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Seagen shareholder, click here to learn more about your rights and options .
  • If you are a Adaptimmune shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis

Retrieved on: 
Saturday, March 18, 2023
American Academy of Dermatology, Oregon Health and Science University Center for Women's Health, Clinical trial, Quality of life, American Academy, Atopic dermatitis, Regeneron Pharmaceuticals, Patient, AAD, Annual general meeting, Itch, Human, Skin, Vaccine, Pharmaceutical industry, Dupilumab, Sanofi

TARRYTOWN, N.Y. and PARIS, March 18, 2023 (GLOBE NEWSWIRE) --  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the clinical trial assessing Dupixent® (dupilumab) in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermatitis. The trial, the first evaluating a biologic for this difficult-to-treat population, met its primary and key secondary endpoints. The results were featured in a late-breaking session, one of more than 20 Dupixent scientific presentations, at the American Academy of Dermatology (AAD) 2023 Annual Meeting.

Key Points: 
  • The trial, the first evaluating a biologic for this difficult-to-treat population, met its primary and key secondary endpoints.
  • The results were featured in a late-breaking session, one of more than 20 Dupixent scientific presentations, at the American Academy of Dermatology (AAD) 2023 Annual Meeting.
  • There were significant improvements in measures of hand and foot skin pain, sleep, and hand eczema-related quality of life.
  • The trial demonstrated similar safety results to the known safety profile of Dupixent in atopic dermatitis.

(PRVB): Johnson Fistel Investigates Proposed Sale of Provention Bio Inc.; Is $25.00 a Fair Price?

Retrieved on: 
Friday, March 17, 2023
Learning, LLP, SAN, Acquisition, Type 1, Patient, T1D, Sale, Pharmaceutical industry, Sanofi

SAN DIEGO, March 17, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Provention Bio Inc. (Nasdaq - PRVB) breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi (Nasdaq – SNY).

Key Points: 
  • SAN DIEGO, March 17, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Provention Bio Inc. (Nasdaq - PRVB) breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi (Nasdaq – SNY).
  • On March 13, 2023, Provention announced that it has entered into a definitive agreement to be acquired by Sanofi, in an all-cash transaction; Provention stockholders would receive $25.00 per share in cash.
  • Johnson Fistel is investigating whether the proposed deal represents adequate consideration, especially given the $9.6 billion estimated global market opportunity for Type 1 diabetes drugs by 2030.
  • If you are a shareholder of Provention and believe the proposed buyout price is too low or you're interested in learning more about the investigation, please contact lead analyst Jim Baker ( [email protected] ) at 619-814-4471.